IGC Pharma Inc
For the period ended Dec 31, 2023. Filed Feb 14, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Dec 31, 2023 · Filed Feb 14, 2024
IGC$0.20-4.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations and Comprehensive Loss
(in thousands, except loss per share and share data)
| Three months ended December 31, | Nine months ended December 31, | |||
|---|---|---|---|---|
| 2023 | 2022 | 2023 | 2022 | |
| ($) | ($) | ($) | ($) | |
| Revenue | 204 | 332 | 1,050 | 745 |
| Cost of revenue | (71) | (230) | (488) | (366) |
| Gross profit | 133 | 102 | 562 | 379 |
| Selling, General and Administrative expenses | (2,228) | (1,574) | (5,272) | (4,943) |
| Research and development expenses | (903) | (806) | (2,918) | (2,968) |
| Operating loss | (2,998) | (2,278) | (7,628) | (7,532) |
| Impairment Loss on PPE | (2,623) | - | (2,623) | - |
| Other income, net | 32 | 29 | 136 | 56 |
| Loss before income taxes | (5,589) | (2,249) | (10,115) | (7,476) |
| Income tax expense/benefit | - | - | - | - |
| Net loss attributable to common stockholders | (5,589) | (2,249) | (10,115) | (7,476) |
| Foreign currency translation adjustments | 18 | (61) | (36) | (462) |
| Comprehensive loss | (5,571) | (2,310) | (10,151) | (7,938) |
| Net loss per share attributable to common stockholders: | ||||
| Basic and diluted | $(0.09) | (0.04) | (0.18) | (0.14) |
| Weighted-average number of shares used in computing net loss per share amounts: | 63,725,084 | 53,063,473 | 57,039,035 | 52,412,830 |
| December 31, 2023, Form 10-Q
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.